Temsirolimus + Etoposide + Cyclophosphamide + Methotrexate + Hydrocortisone + Cytarabine
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lymphoblastic Leukemia, Acute, Childhood
Conditions
Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Lymphoma, Peripheral T-cell Lymphoma
Trial Timeline
Jul 3, 2015 → Sep 4, 2020
NCT ID
NCT01614197About Temsirolimus + Etoposide + Cyclophosphamide + Methotrexate + Hydrocortisone + Cytarabine
Temsirolimus + Etoposide + Cyclophosphamide + Methotrexate + Hydrocortisone + Cytarabine is a phase 1 stage product being developed by Pfizer for Lymphoblastic Leukemia, Acute, Childhood. The current trial status is completed. This product is registered under clinical trial identifier NCT01614197. Target conditions include Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Lymphoma, Peripheral T-cell Lymphoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01614197 | Phase 1 | Completed |
Competing Products
20 competing products in Lymphoblastic Leukemia, Acute, Childhood